miR-106a-363 cluster host gene (MIR106AHG)

The miR-106a-363 cluster host gene (MIR106AHG) encodes a cluster of six microRNAs—miR-106a, miR-18b, miR-19b-2, miR-20b, miR-92a-2, and miR-363—located on chromosome X (Xq26.2) in humans[1][3]. The gene itself is a non-coding RNA locus that provides the primary transcript for the miR-106a-363 cluster, rather than serving as a protein-coding therapeutic target. These microRNAs regulate key biological processes, including cell cycle progression, apoptosis, cell differentiation, immune cell function, and angiogenesis[1][2][5]. Dysregulation of individual members of this cluster has been implicated in tumorigenesis (e.g., breast cancer, hepatocellular carcinoma, neuroblastoma), immune-related diseases (e.g., multiple sclerosis, Crohn's disease), and age-related tissue changes[2][5]. Experimental evidence demonstrates that the cluster is important for fine-tuning T helper cell fate and Th17 differentiation, which is linked to various autoimmune and inflammatory pathologies[4][5]. Members can act with either oncogenic or tumor suppressive function depending on cell context, but the MIR106AHG "host gene" itself is not a classical drug target or protein, and no approved drugs specifically target it[1][2][5]. MIR106AHG refers to the non-coding host gene that produces the miR-106a-363 microRNA cluster. While the cluster members have functional and pathogenic roles (and may be considered therapeutic targets at the miRNA level), the "host gene" itself is not a canonical therapeutic target. If you are interested in the cluster or its individual microRNAs (such as miR-106a or miR-363), those may warrant further entries.

Other names

MIR106AHGmiR-106a-363 clustermiR-106a~363 clustermiRNA-106a-363 cluster